An Early Phase 1 interventional study of SASS in Epidermolysis Bullosa Dystrophica, sponsored by CHU de Quebec-Universite Laval. Active, not recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by CHU de Quebec-Universite Laval · Early Phase 1, Interventional, and Treatment
Single patient study. Patient diagnosed with dystrophic epidermolysis bullosa presenting chronic open wounds that are not responding to dressings, topical preparations (antimicrobials, antibiotics) and systemic agents (anti-inflammatory antibacterials). The Self-Assembled Skin Substitutes will be used to cover wounds.
77 studies on the registry are indexed under Epidermolysis Bullosa Dystrophica; 20 are open to participants now.
This study's enrollment of 1 is below the median of 9 across 54 interventional studies indexed under Epidermolysis Bullosa Dystrophica.
Browse Epidermolysis Bullosa Dystrophica studies →CHU de Quebec-Universite Laval is the lead sponsor of 134 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This clinical trial was custom designed for one patient
SASS applied on chronic skin wounds as skin graft
Biological: SASS
SASS applied on chronic skin wounds as skin graft
Percent reduction in wound surface area
Clinical assessment
Time frame: 2 weeks
Graft failure
Clinical assessment
Time frame: 2 weeks
Number of subsequent re-transplantation
Number
Time frame: 3 years
Time (in weeks) to 50% reduction in the surface area of the wounds;
Clinical assessment
Time frame: 3 years
Time (in weeks) to complete healing
Clinical assessment
Time frame: 3 years
Changes in pain scores
10 point visual analog scale where 0 is none and 10 the worst pain
Time frame: 3 years
Changes in itch scores where 0 is none and 10 the worst itch
10 point scale
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epidermolysis Bullosa Dystrophica→
CHU de Quebec-Universite Laval